CannaPharmaRX, Inc.
CPMD
$0.0055
$0.000.00%
| Weiss Ratings | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C- | |||
| Rating Factors | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 163.73 | |||
| Price History | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 14.58% | |||
| 30-Day Total Return | 37.50% | |||
| 60-Day Total Return | -34.52% | |||
| 90-Day Total Return | -29.49% | |||
| Year to Date Total Return | -30.38% | |||
| 1-Year Total Return | -64.52% | |||
| 2-Year Total Return | -35.29% | |||
| 3-Year Total Return | -57.36% | |||
| 5-Year Total Return | -98.90% | |||
| 52-Week High % Change | -68.75% | |||
| 52-Week Low % Change | 5,400.00% | |||
| Price | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.02 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | May 17, 2024 | |||
| 52-Week High Price (Date) | May 23, 2024 | |||
| Valuation | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.61M | |||
| Enterprise Value | 18.63M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -79.56% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 11.00 | |||
| Price/Book (Q) | -0.21 | |||
| Enterprise Value/Revenue (TTM) | 55.12 | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -18.18 | |||
| Enterprise Value/EBIT | -15.42 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 662.50M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 403-637-0420 | |||
| Address | 888 3rd Street SW Calgary, AB T2P 5C5 | |||
| Website | www.cannapharmarx.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -357.48% | |||
| Profit Margin | 408.31% | |||
| Management Effectiveness | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -8.97% | |||
| Return on Equity | -- | |||
| Income Statement | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 338.00K | |||
| Total Revenue (TTM) | 338.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -1.14M | |||
| EBITDA (TTM) | -1.02M | |||
| EBIT (TTM) | -1.21M | |||
| Net Income (TTM) | 1.38M | |||
| Net Income Avl. to Common (TTM) | 1.38M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 133.38% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 115.79% | |||
| Balance Sheet | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 7.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 1.50M | |||
| Total Preferred Equity (Q) | 0.63 | |||
| Total Equity (Q) | -16.58M | |||
| Current Ratio (Q) | 0.067 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 11.68M | |||
| Total Current Liabilities (Q) | 22.50M | |||
| Total Debt (Q) | 14.40M | |||
| Total Liabilities (Q) | 28.27M | |||
| Total Common Equity (Q) | -17.21M | |||
| Cash Flow | CPMD - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.80K | |||
| Cash from Financing (TTM) | 2.83M | |||
| Net Change in Cash (TTM) | 7.10K | |||
| Levered Free Cash Flow (TTM) | 710.90K | |||
| Cash from Operations (TTM) | -2.82M | |||
